Sorrento Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sorrento Therapeutics generated cash of -$293,857,000, which is less than the previous year. Cash used in financing activities reached the amount of $311,718,000 last year. Net change in cash is therefore -$13,031,000.
Cash Flow
| 2013 | -16.48M | -503.48K | 43.56M |
|---|---|---|---|
| 2014 | -28.76M | -10.59M | 79.59M |
| 2015 | -42.06M | 12.55M | -3.34M |
| 2016 | -70.89M | -17.45M | 131.74M |
| 2017 | -99.18M | -16.52M | 53.67M |
| 2018 | -111.76M | -21.19M | 325.99M |
| 2019 | -172.99M | -38.17M | 78.88M |
| 2020 | -159.53M | -39.92M | 174.23M |
| 2021 | -281.82M | 79.84M | 181.33M |
| 2022 | -293.85M | -28.51M | 311.71M |
SRNE Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 36.66M | 56.46M | 80.76M | 213.33M | 20.42M | 82.39M | 39.03M | 71.90M | 31.66M | 5.09M |
Operating activities | ||||||||||
Net income | -577.75M | -429.13M | -314.41M | -363.01M | -212.52M | 9.06M | -63.93M | -50.07M | -34.65M | -21.91M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 13.24M | 12.46M | 11.00M | 10.98M | 9.05M | 7.08M | 2.88M | 2.37M | 3.18M | 1.29M |
Stock-based compensation expense | 74.84M | 90.18M | 31.41M | 12.64M | 0 | 4.95M | 4.74M | 6.97M | 3.94M | 1.78M |
| Deferred income tax benefit | 74.84M | 90.18M | 31.41M | 12.64M | 0 | 4.95M | 4.74M | 6.97M | 3.94M | 1.78M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -5.68M | -2.95M | -1.05M | -10.62M | 0 | -515K | 0 | -176K | 0 | 116.75K |
Inventories | -9.51M | 8.61M | 10.20M | 0 | 0 | 0 | 0 | 7.81M | 0 | 0 |
Accounts payable | 9.87M | -3.87M | -3.67M | 10.22M | 3.57M | 1.59M | 3.71M | -2.71M | -497K | 878.64K |
Cash generated by operating activities | -293.85M | -281.82M | -159.53M | -172.99M | -111.76M | -99.18M | -70.89M | -42.06M | -28.76M | -16.48M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -9.69M | 0 | -5M | 0 | -11.5M | -10M | 0 |
Investments In Property Plant And Equipment | -13.65M | -8.87M | -37.57M | -11.44M | -11.19M | -10.97M | -6.86M | -3.70M | -591K | -931.29K |
Acquisitions Net | -14.86M | -36.04M | -2.34M | -9.69M | 0 | -557K | -10.59M | 27.75M | 0 | 427.81K |
Cash generated by investing activities | -28.51M | 79.84M | -39.92M | -38.17M | -21.19M | -16.52M | -17.45M | 12.55M | -10.59M | -503.48K |
Financing activities | ||||||||||
Common Stock Issued | 402.33M | 201.82M | 317.86M | 47.69M | 83.60M | 57.92M | 107.98M | 0 | 71.78M | 37.70M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -55M | 0 | 0 | 0 | -15.63M | 0 | 0 | 37.70B |
Repayments of term debt | -92.24M | -85.65M | -205.56M | 22.33M | -45.72M | -3.24M | -9.45M | -3.09M | 0 | 0 |
Cash used in financing activities | 311.71M | 181.33M | 174.23M | 78.88M | 325.99M | 53.67M | 131.74M | -3.34M | 79.59M | 43.56M |
Net Change In Cash | -13.03M | -19.79M | -24.30M | -132.56M | 192.90M | -61.96M | 43.36M | -32.86M | 40.23M | 26.57M |
Cash at end of period | 23.63M | 36.66M | 56.46M | 80.76M | 213.33M | 20.42M | 82.39M | 39.03M | 71.90M | 31.66M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |